Key Differences Between Vyvanse and Adderall
Vyvanse (lisdexamfetamine) is a prodrug that requires enzymatic conversion to active d-amphetamine in the blood, while Adderall (mixed amphetamine salts) contains immediate-release amphetamine that is active upon ingestion. 1
Mechanism and Pharmacology
Chemical Structure
- Vyvanse is lisdexamfetamine dimesylate—a prodrug consisting of d-amphetamine covalently bonded to the amino acid l-lysine 2, 3
- Adderall contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine) that are pharmacologically active immediately 1
Activation Process
- Vyvanse remains pharmacologically inactive until red blood cells enzymatically hydrolyze it to release d-amphetamine and l-lysine 2, 4
- Adderall requires no conversion and begins working immediately after absorption 5
Pharmacokinetic Profile
- Vyvanse has a delayed onset with a lag time approximately 0.6 hours longer and reaches peak levels about 1.1 hours later than equivalent doses of d-amphetamine 5
- Adderall (immediate-release formulations) reaches peak concentrations more rapidly 5
- Both achieve similar maximal concentrations and total drug exposure (AUC) when given in equimolar doses 5
Clinical Implications
Duration of Action
- Vyvanse provides once-daily dosing with effects lasting up to 14 hours post-dose in adults, making it suitable for managing symptoms extending late into the day 4
- Adderall XR (extended-release) also provides once-daily dosing but through different controlled-release bead technology 1
Abuse Potential
- Vyvanse has theoretically lower oral abuse potential because the prodrug design limits the rate of d-amphetamine release through enzymatic hydrolysis 1, 3
- The American Academy of Pediatrics notes that lisdexamfetamine is more difficult to extract for misuse compared to immediate-release amphetamines 1
- However, research shows that when taken orally at therapeutic doses, peak subjective effects (drug liking, euphoria) are similar between lisdexamfetamine and d-amphetamine, just delayed in onset 5
- Adderall immediate-release formulations have higher diversion risk, particularly in adolescents 1
Dosing Considerations
Vyvanse: 1
- Starting dose: 20-30 mg once daily in the morning
- Titration: Increase by 10 mg weekly
- Maximum: 70 mg daily
Adderall XR: 1
- Starting dose: 10 mg once daily in the morning
- Titration: Increase by 5 mg weekly
- Maximum: 50 mg daily
Side Effect Profile
- Both medications produce similar adverse effects including decreased appetite, sleep disturbances, increased blood pressure and heart rate, headaches, irritability, and stomach pain 1
- Both require monitoring of blood pressure, heart rate, weight, and height in children 1, 6
- Peak cardiovascular and subjective stimulant effects occur later with Vyvanse but reach similar magnitudes as Adderall 5
Special Populations
Pregnancy and Lactation
- Both medications have similar safety profiles in pregnancy with reassuring data regarding major congenital malformations 1
- Both carry possible small increased risks for gastroschisis, preeclampsia, and preterm birth when used in the second half of pregnancy 1
- Both are classified as Hale lactation risk category L3 1
- Limited published data exists specifically for lisdexamfetamine in pregnancy, but since it converts to dextroamphetamine, the amphetamine safety data applies 1
Adolescents at Risk for Diversion
- Vyvanse is preferred when diversion risk is a concern because the prodrug formulation makes extraction more difficult and provides no advantage when crushed or snorted 1
- Adderall immediate-release has higher diversion potential 1
Common Pitfalls
- Do not assume Vyvanse has dramatically lower abuse potential—while the prodrug design delays onset, oral administration produces similar peak subjective effects as d-amphetamine 5
- Both medications require the same cardiovascular monitoring—neither is safer regarding blood pressure or heart rate effects 1, 6, 5
- Do not use interchangeable dosing—Vyvanse doses are not equivalent to Adderall doses due to different salt formulations and the prodrug design 1